Nosocomial Infection Treatment Market: Introduction
- Nosocomial infection is termed as infection caused within 48 hours of hospital admission. Hence, it is also known as hospital-acquired infection. Patients in intensive care units (ICU) are more prone to hospital-acquired infections.
- About 90% hospital-acquired infections are bacterial infections. E. coli, P. aeruginosa, and S. aureus are the most common bacteria responsible for urinary and respiratory tract infections, wound, kidney, and blood infection. Excessive and misuse of antibiotics has led to increase in number of nosocomial infections.
Key Drivers and Opportunities of Global Nosocomial Infection Treatment Market
- Increase in incidence of hospital-acquired infections is projected to boost the growth of the global nosocomial infection treatment market. According to the Centers for Disease Control and Prevention, an estimated 1.7 million infections and 99,000 deaths occur due to healthcare-acquired infections in hospitals in the U.S. each year.
- Moreover, rise in prevalence of nosocomial infections such as urinary tract infection, tuberculosis, surgical wound infection, and respiratory tract infection is anticipated to fuel the growth of the global market. According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, approximately 60% of women have symptomatic UTI during their lifetime and in the U.S., around 10% women have one or more than one UTI episodes each year. According to the World Health Organization, globally, an estimated 10 million people fell ill with tuberculosis in 2018. According to the Centers for Disease Control and Prevention, around 157,500 surgical site infections are reported in the U.S. each year.
Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure of Nosocomial Infection Treatment Market Report
- Antibiotics are the most commonly prescribed treatments for nosocomial infections. Excessive use of antibiotics leads to microbial antibiotic resistance. Hence, development of new antibiotics is underway in order to overcome multiple drug resistance. For instance, in July 2019, the U.S. Food and Drug Administration approved the antibacterial drug, Recarbrio, for the treatment of complicated UTIs and complicated intra-abdominal infection in adults.
- In February 2018, Allergan received the U.S. Food and Drug Administration approval for New Drug Application of Avycaz. The drug was approved for the treatment of patients with ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
- Increase in demand for new antibiotics for effective therapy presents considerable opportunity to manufacturers in the market
- Rise in prevalence of nosocomial infections in developing countries creates lucrative opportunities in the global market. According to the Second Australian Atlas of Healthcare Variation, an estimated 73,777 hospitalizations for kidney and urinary tract infections were reported in Australia in 2014–2015.
North America to Capture Major Share of Global Nosocomial Infection Treatment Market
- North America is expected to account for major share of the global nosocomial infection treatment market during the forecast period due to presence of key players and product launch & approvals. Moreover, rise in prevalence of nosocomial infections is likely to fuel the growth of the market in the region. According to the American Urology Association, the estimated incidence of UTI is 0.5 to 0.7 per person per year in premenopausal women in the U.S.
- The nosocomial infection treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in awareness and surge in geriatric population.
Looking for Regional Analysis or Competitive Landscape in Nosocomial Infection Treatment Market, Ask for a Customized Report
Key Players Operating in Global Nosocomial Infection Treatment Market
The global nosocomial infection treatment market is highly consolidated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Growth strategies adopted by key players are likely fuel the growth of the global market. For instance, in July 2018, Nabriva Therapeutics plc acquired Zavante Therapeutics. This acquisition enabled the company to strengthen its leading positioning and develop new anti-infectives.
Major players operating in the global nosocomial infection treatment market are:
- Pfizer, Inc.
- Bayer AG
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Almirall, S.A.
- Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
- Dr. Reddy’s Laboratories Ltd.
- Lupin Pharmaceuticals, Inc.
- Johnson & Johnson's (Janssen Global Services, LLC)
Global Nosocomial Infection Treatment Market: Research Scope
Global Nosocomial Infection Treatment Market, by Drug Class
Global Nosocomial Infection Treatment Market, by Type of Infection
- Ventilator-associated Pneumonia
- Urinary Tract Infection
- Legionnaires’ Disease
- Surgical Wound Infection
- Lower Respiratory Tract Infection
- Surgical Site Infections
Global Nosocomial Infection Treatment Market, by Infectious Agent
Global Nosocomial Infection Treatment Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Nosocomial Infection Treatment Market, by Region
- North America
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.